TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 2892729
Drug: 15‐methyl‐PGF2 alpha
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15‐methyl‐PGF2 alpha (Prostin 15M), 0.25 mg every second hour
Study: 2892729
Drug: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16‐phenoxy‐omega‐17,18,19,20‐tetranor PGE2 methyl sulfonylamide (Nalodor), 0.5 mg every fourth hour
Study: 28958437
Drug: Clobazam 40
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 40 mg/d
Study: 28958437
Drug: Clobazam 160
Normalized name: Clobazam
DrugBank: Clobazam (DB00349)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Clobazam 160 mg/d
Study: 17328944
Drug: Bradykinin (BK)
Normalized name: dimethicone
DrugBank: Bradykinin (DB12126)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Bradykinin (BK) administered at graded doses (0.2, 0.6, and 2.0 microg/min)
Study: 17328944
Drug: Papaverine (PA)
DrugBank: Papaverine (DB01113)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Papaverine (PA) administered at 12 mg
Study: 11715357
Drug: 10 mg
Normalized name: biotin 10 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 10 mg of ramipril
Study: 3138131
Drug: Amiloride (15
Approvals — FDA: no, EMA: no, PMDA: no
Description: Amiloride (15 mg p.o.)
Study: 26152693
Drug: Mixed group
Normalized name: Humalog Mix
Approvals — FDA: no, EMA: no, PMDA: no
Description: Mixed group of other glaucoma medications (S2)
Study: 24092827
Drug: Oral estradiol
Normalized name: estradiol Oral Tablet
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral estradiol (1 mg/d)
Study: 21345418
Drug: Enhanced Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Cognitive Behaviour Therapy (CBT‐E), average of 20‐40 individual sessions with a clinical psychologist
Study: 21345418
Drug: Enhanced Cognitive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Enhanced Cognitive Behaviour Therapy (CBT‐E)
Study: 18603204
Drug: Elective treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Elective treatment of the neck lymphatics
Study: 18543684
Drug: Systane treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Systane treatment (Group A)
Study: 18543684
Drug: Purified water
Normalized name: Purified water
DrugBank: Water (DB09145)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Purified water treatment (Group B)
Study: 15605331
Drug: Home exercise
Normalized name: benzalkonium
DrugBank: Benzalkonium (DB11105)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Home exercise program (12-week duration, including hip flexion range of motion exercises, strengthening exercises for bilateral hip flexors, extensors, and abductors, and a daily 30-minute walk)
Study: 30946851
Drug: Oral agents
Normalized name: DENTAL AND ORAL AGENTS,TOPICAL
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral agents including sulphonylurea
Study: 26299164
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid (LAc) treatment in low P diet
Study: 26299164
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (CAc) treatment in low P diet
Study: 26299164
Drug: Lactic acid
Normalized name: Lactic Acid
DrugBank: Lactic acid (DB04398)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Lactic acid (LAc) treatment
Study: 26299164
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (CAc) treatment
Study: 26299164
Drug: Citric acid
Normalized name: Citric Acid
DrugBank: Citric acid (DB04272)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Citric acid (CAc) and Lactic acid (LAc) treatments
Study: 24464531
Drug: Combination of
Normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination of Naltrexone (50 mg) and Alprazolam (0.5 mg)
Study: 24464531
Drug: Oral d-amphetamine
Normalized name: amphetamine / dextroamphetamine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral d-amphetamine (0, 15, and 30 mg)
Study: 10812285
Drug: Naltrexone (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naltrexone (0 mg)
Study: 24464531
Drug: Alprazolam (0
Approvals — FDA: no, EMA: no, PMDA: no
Description: Alprazolam (0 mg)
Study: 19554672
Drug: Geriatric Depression
Normalized name: CATHETER,EXTERNAL CONVEEN #5120 GERIATRIC/PEDIATRIC
Approvals — FDA: no, EMA: no, PMDA: no
Description: Geriatric Depression Scale (GDS) administered every 2 weeks for 6 months
Study: 14982884
Drug: CHOEP (CHOP
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOEP (CHOP plus etoposide 100 mg/m2 days 1-3)
Study: 14982884
Drug: CHOP (standard
Approvals — FDA: no, EMA: no, PMDA: no
Description: CHOP (standard chemotherapy)
Study: 11195894
Drug: Anger expression
Normalized name: After banger
DrugBank: Levonorgestrel (DB00367)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Anger expression (e.g., President Clinton expressing anger about the Monica Lewinsky scandal)
Study: 11195894
Drug: Sadness expression
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sadness expression (e.g., President Clinton expressing sadness about the Monica Lewinsky scandal)
Study: 9625131
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mesalazine b.i.d.
Study: 9625131
Drug: 500 mg
Normalized name: bran 500 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: 500 mg mesalazine u.i.d.
Study: 3310626
Drug: Sucralfate (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sucralfate (1 g suspension every four hours)
Study: 3310626
Drug: Antacid (administered
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antacid (administered every two hours)
Study: 19923038
Drug: 15-30 mg
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: 15-30 mg pioglitazone daily (n=21, pioglitazone group)
Study: 19946230
Drug: L-arginine (2
Approvals — FDA: no, EMA: no, PMDA: no
Description: L-arginine (2 g tid for 3 months)
Study: 17461852
Drug: Intramuscular ALCAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ALCAR 500 mg bid for 14 days followed by oral ALCAR 1000 mg bid for 42 days
Study: 17461852
Drug: Intramuscular ALCAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intramuscular ALCAR
Study: 17461852
Drug: Oral ALCAR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral ALCAR
Study: 9367461
Drug: Bivalent live
Normalized name: fecal microbiota, live Enema [Rebyota]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Bivalent live attenuated influenza A virus vaccine (CAV)
Study: 9367461
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza virus vaccine (TVV)
Study: 9367461
Drug: Trivalent inactivated
Normalized name: diphtheria toxoid vaccine, inactivated / tetanus toxoid vaccine, inactivated Injection [Tdvax]
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trivalent inactivated influenza virus vaccine (TVV) and intranasal placebo
Study: 9367461
Drug: Combination vaccine
Normalized name: Hepatitis vaccine combinations
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combination vaccine regimen (CAV and TVV)
Study: 9367461
Drug: TVV and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: TVV and intranasal placebo
Study: 3895150
Drug: Tracheal instillation
Normalized name: bovine type II collagen (tracheal cartilage)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tracheal instillation of surfactant (3 or 4 mL, prepared from calf lung lavage)
Study: 22459543
Drug: 0.5 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.5 mL/kg autologous blood (Group A)
Study: 22459543
Drug: 1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL/kg autologous blood (Group B)
Study: 22459543
Drug: 2 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2 mL/kg autologous blood (Group C)
Study: 22459543
Drug: 1 mL/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 1 mL/kg normal saline (Group D)
Study: 15933967
Drug: Postoperative supplemental
Approvals — FDA: no, EMA: no, PMDA: no
Description: Postoperative supplemental oxygen (8 L/min for 6 hours)
Study: 15933967
Drug: Routine care
Approvals — FDA: no, EMA: no, PMDA: no
Description: Routine care (5 L/min oxygen in PACU, no supplemental oxygen on the ward)
Study: 11071800
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with reduced dose reteplase (5+5 U)
Study: 11071800
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with reduced dose reteplase (10+5 U)
Study: 11071800
Drug: standard dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: standard dose reteplase (10+10 U)
Study: 11071800
Drug: abciximab with
Normalized name: Abciximab
DrugBank: Abciximab (DB00054)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: abciximab with reduced dose reteplase (5+5 U or 10+5 U)
Study: 1533771
Drug: Isradipine (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Isradipine (5 to 10 mg/day)
Study: 1533771
Drug: Metoprolol (100
Approvals — FDA: no, EMA: no, PMDA: no
Description: Metoprolol (100 to 200 mg/day)
Study: 31141081
Drug: Optimized calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized calorie and high protein nutrition therapy (2.0 to 2.2g/kg/day protein)
Study: 31141081
Drug: Optimized calorie
Approvals — FDA: no, EMA: no, PMDA: no
Description: Optimized calorie and high protein nutrition therapy
Study: 30543657
Drug: Sanofi Pasteur
Normalized name: Sanofi Pasteur COVID-19 Vaccine, Adjuvanted For Booster Immunization PF
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sanofi Pasteur recombinant, live, attenuated, tetravalent vaccine (CYD‐TDV)
Study: 25297613
Drug: Dietary fiber
Normalized name: Dietary Fiber 1.67 GM Oral Tablet, Chewable
Approvals — FDA: no, EMA: no, PMDA: no
Description: Dietary fiber materials (DFMs) including polydextrose, partially hydrolysed guar gum, resistant maltodextrin, partially hydrolysed alginate, glucomannan, heat‐moisture treatment, high‐amylose cornstarch, cellulose
Study: 20530317
Drug: Armodafinil 150
Normalized name: armodafinil 150 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Armodafinil 150 mg/d
Study: 9164520
Drug: Combined therapy
Normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined therapy (Endoscopic Variceal Ligation + EIS)
Study: 7970945
Drug: Rhesus-human reassortant
Normalized name: human-bovine reassortant rotavirus strain G4 vaccine
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rhesus-human reassortant tetravalent oral rotavirus vaccine (4 x 10^4 plaque-forming units)
Study: 3556051
Drug: Salbutamol from
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salbutamol from metered-dose inhaler (MDI)
Study: 1978667
Drug: Flumazenil (20
Approvals — FDA: no, EMA: no, PMDA: no
Description: Flumazenil (20 mg)
Study: 1125653
Drug: Plasma immunoreactive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Plasma immunoreactive beta‐melanocyte stimulating hormone (beta‐MSH) concentrations
Study: 31726714
Drug: Winter ice-cream
Normalized name: winter savory oil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Winter ice-cream intake
Study: 31726714
Drug: Milk-based desserts
Approvals — FDA: no, EMA: no, PMDA: no
Description: Milk-based desserts (no winter ice cream)
Study: 26004031
Drug: 6-week program
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6-week program of enhanced physiotherapy and structured exercise (PEPSE) and essential amino acid supplement drink (glutamine and essential amino acid mixture [GEAA])
Study: 26004031
Drug: GEAA supplement
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEAA supplement with PEPSE
Study: 26004031
Drug: Control supplement/PEPSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: Control supplement/PEPSE
Study: 26004031
Drug: GEAA supplement/PEPSE
Approvals — FDA: no, EMA: no, PMDA: no
Description: GEAA supplement/PEPSE
Study: 24229738
Drug: GeneSight pharmacogenomic-informed
Normalized name: INFORMATION
Approvals — FDA: no, EMA: no, PMDA: no
Description: GeneSight pharmacogenomic-informed treatment (n=26)
Study: 24229738
Drug: Treatment as
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Treatment as usual (TAU) (n=25)
Study: 8487513
Drug: Drug and
Normalized name: cytarabine and daunorubicin
Approvals — FDA: no, EMA: no, PMDA: no
Description: Drug and alcohol abuse prenatal care health education program
Study: 3324648
Drug: Citalopram (40
Approvals — FDA: no, EMA: no, PMDA: no
Description: Citalopram (40 or 60 mg)
Study: 3324648
Drug: Maprotiline (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: Maprotiline (75 or 150 mg)
Study: 20978447
Drug: 7.5 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 7.5 mg/kg bevacizumab
Study: 20978447
Drug: 15 mg/kg
Approvals — FDA: no, EMA: no, PMDA: no
Description: 15 mg/kg bevacizumab
Study: 16322492
Drug: FNS‐IM (Functional
Approvals — FDA: no, EMA: no, PMDA: no
Description: FNS‐IM (Functional Neuromuscular Stimulation using intramuscular electrodes)
Study: 11286465
Drug: Megestrol 160
Normalized name: megestrol acetate 160 MG
Approvals — FDA: no, EMA: no, PMDA: no
Description: Megestrol 160 mg day(-1)
Study: 9240185
Drug: tamsulosin (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: tamsulosin (0.2 mg/day)
Study: 9240185
Drug: allylestrenol (50
Approvals — FDA: no, EMA: no, PMDA: no
Description: allylestrenol (50 mg/day)
Study: 8214993
Drug: Lovastatin, 80
Approvals — FDA: no, EMA: no, PMDA: no
Description: Lovastatin, 80 mg/day
Study: 3312862
Drug: Sunscreen cream
Normalized name: GLYCERIN 1 g in 50 g TOPICAL CREAM [SUNSCREEN Cream]
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen cream (Pabafil SPF 10, with absorption range from 290 to 360 nm)
Study: 3312862
Drug: Sunscreen cream
Normalized name: GLYCERIN 1 g in 50 g TOPICAL CREAM [SUNSCREEN Cream]
DrugBank: Homosalate (DB11064)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Sunscreen cream
Study: 24738609
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR (500 mg/day)
Study: 24738609
Drug: Tapentadol PR
Approvals — FDA: no, EMA: no, PMDA: no
Description: Tapentadol PR (300 mg/day) / Pregabalin (300 mg/day)
Study: 23672789
Drug: Pitavastatin 2‐4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pitavastatin 2‐4 mg/day
Study: 23672789
Drug: Atorvastatin 10‐20mg/day
Approvals — FDA: no, EMA: no, PMDA: no
Description: Atorvastatin 10‐20mg/day
Study: 21732669
Drug: Selenium-fortified broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Selenium-fortified broccoli (200 g daily for 4 weeks)
Study: 21732669
Drug: Regular broccoli
Approvals — FDA: no, EMA: no, PMDA: no
Description: Regular broccoli (200 g daily for 4 weeks)
Study: 16874778
Drug: Infliximab (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Infliximab (5 mg/kg) administered at weeks 0, 2, 6, and every 6 weeks thereafter through week 24
Study: 10837017
Drug: Rye crispbread
Normalized name: Rye
DrugBank: Rye (DB10564)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Rye crispbread (76.5 g/day for 2 weeks)
Study: 8780091
Drug: Standard carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard carbidopa/levodopa (Std‐L)
Study: 8780091
Drug: Sustained-release carbidopa/levodopa
Approvals — FDA: no, EMA: no, PMDA: no
Description: Sustained-release carbidopa/levodopa (L‐CR)
Study: 1473430
Drug: Misoprostol (200
Approvals — FDA: no, EMA: no, PMDA: no
Description: Misoprostol (200 micrograms four times daily with meals and at bedtime)
Study: 30888118
Drug: Rituximab maintenance
Normalized name: Rituximab
DrugBank: Rituximab (DB00073)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Rituximab maintenance treatment (375 mg/m2 q3 months for 2 years)
Study: 26840703
Drug: Intracutaneous sterile
Normalized name: Steril-Eyes
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intracutaneous sterile water injections (ISWI)
Study: 26840703
Drug: Intracutaneous isotonic
Normalized name: sodium chloride
DrugBank: Sodium chloride (DB09153)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Intracutaneous isotonic saline injections (placebo treatment)
Study: 22742888
Drug: Vision restoration
Approvals — FDA: no, EMA: no, PMDA: no
Description: Vision restoration therapy
Study: 12558088
Drug: Preoperative oral
Normalized name: povidone-iodine
DrugBank: Povidone-iodine (DB06812)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Preoperative oral slow-release tramadol
Study: 10217370
Drug: 2.4 g
Normalized name: ZINC OXIDE 12.4 g in 100 g TOPICAL CREAM
Approvals — FDA: no, EMA: no, PMDA: no
Description: 2.4 g aged garlic extract (AGE)
Study: 10217370
Drug: 0.8 g
Normalized name: Alcohol 0.8 g in 1 mL TOPICAL LIQUID
Approvals — FDA: no, EMA: no, PMDA: no
Description: 0.8 g DL‐alpha‐tocopherol acetate
Study: 10217370
Drug: 6 g
Normalized name: FAPi-46 GA-68
DrugBank: FAPi-46 GA-68 (DB18827)
Approvals — FDA: no, EMA: no, PMDA: no
Description: 6 g raw garlic
Study: 7038316
Drug: Low-dose verapamil
Normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
Approvals — FDA: yes, EMA: no, PMDA: yes
Description: Low-dose verapamil (0.075 mg/kg)
Study: 7038316
Drug: Standard-dose verapamil
Approvals — FDA: no, EMA: no, PMDA: no
Description: Standard-dose verapamil (0.15 mg/kg)
Study: 7038316
Drug: Verapamil (low-dose
Approvals — FDA: no, EMA: no, PMDA: no
Description: Verapamil (low-dose and standard-dose)
Study: 31630358
Drug: TAT-SOD (0.2
Approvals — FDA: no, EMA: no, PMDA: no
Description: TAT-SOD (0.2 mL of 3000 U/mL TAT-SOD cream) applied topically at acupoint ST 36 once a day for 15 days
Study: 31630358
Drug: Placebo cream
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo cream applied topically at acupoint ST 36 once a day for 15 days
Study: 22541893
Drug: Trabectedin plus
Approvals — FDA: no, EMA: no, PMDA: no
Description: Trabectedin plus pegylated liposomal doxorubicin (PLD) 30 mg/m² IV followed by a 3-h infusion of trabectedin 1.1 mg/m² every 3 weeks
Study: 22541893
Drug: PLD 50
Normalized name: pLDLR-Neo
Approvals — FDA: no, EMA: no, PMDA: no
Description: PLD 50 mg/m² every 4 weeks
Study: 18018769
Drug: 16 SU
Normalized name: FLUCELVAX 2015-2016 Suspension for Injection
Approvals — FDA: no, EMA: no, PMDA: no
Description: 16 SU inactivated SARS-CoV vaccine
Study: 18018769
Drug: 32 SU
Normalized name: ZINC OXIDE 25 g in 100 g TOPICAL CREAM [Erins Faces Mineral SPF 32 Sunscreen]
Approvals — FDA: no, EMA: no, PMDA: no
Description: 32 SU inactivated SARS-CoV vaccine
Study: 9920144
Drug: Combined treatment
Normalized name: Hongo Killer Treatment
Approvals — FDA: no, EMA: no, PMDA: no
Description: Combined treatment (gemfibrozil + lovastatin)
Study: 7501353
Drug: Antenatal vitamin
Normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Antenatal vitamin K and phenobarbital therapy
Study: 2253912
Drug: Olsalazine (1
Approvals — FDA: no, EMA: no, PMDA: no
Description: Olsalazine (1 g twice daily)
Study: 2253912
Drug: Pentasa (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pentasa (750 + 500 + 750 mg daily)
Study: 2253912
Drug: Salofalk (750
Approvals — FDA: no, EMA: no, PMDA: no
Description: Salofalk (750 + 500 + 750 mg daily)
Study: 26226884
Drug: Donepezil (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Donepezil (5 and 10 mg)
Study: 19848610
Drug: Intermittent preventive
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intermittent preventive sulfadoxine-pyrimethamine treatment
Study: 17447832
Drug: Pramipexole 0.125,
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole 0.125, 0.25, 0.50 or 0.75 mg once daily for 3 weeks
Study: 17447832
Drug: Pramipexole at
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole at a median dosage of 0.35 mg/day for 6 weeks
Study: 17447832
Drug: Pramipexole after
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pramipexole after 6 months' therapy
Study: 7820492
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition with glutamine supplementation (20 g/day for 3 days)
Study: 7820492
Drug: Total parenteral
Normalized name: TPN - total parenteral nutrition
Approvals — FDA: no, EMA: no, PMDA: no
Description: Total parenteral nutrition without glutamine supplementation
Study: 2205135
Drug: Oral diazepam
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral diazepam 0.33 mg.kg‐1
Study: 2205135
Drug: Normal saline
Normalized name: Normal Saline Flush
Approvals — FDA: no, EMA: no, PMDA: no
Description: Normal saline (placebo) 0.04 ml.kg‐1
Study: 282538
Drug: Pulsed electromagnetic
Approvals — FDA: no, EMA: no, PMDA: no
Description: Pulsed electromagnetic energy therapy
Study: 26485404
Drug: Guanidinoacetic acid
Normalized name: Guanidinoacetic acid
Approvals — FDA: no, EMA: no, PMDA: no
Description: Guanidinoacetic acid (GAA) 3 g/day for 2 weeks
Study: 23410999
Drug: 4-drug fixed-dose
Normalized name: 4-MIXED TRACE ELEMENTS INJ
Approvals — FDA: no, EMA: no, PMDA: no
Description: 4-drug fixed-dose combination (FDC) of rifampicin, isoniazid, ethambutol, and pyrazinamide
Study: 23410999
Drug: Separate formulations
Normalized name: Atractylis separate root
DrugBank: Atractylodes lancea root (DB14693)
Approvals — FDA: no, EMA: no, PMDA: no
Description: Separate formulations of rifampicin, isoniazid, ethambutol, and pyrazinamide
Study: 21422411
Drug: Bevacizumab with
Normalized name: Bevacizumab
DrugBank: Bevacizumab (DB00112)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: Bevacizumab with full-dose anticoagulation
Study: 14764774
Drug: Calcium supplementation
Approvals — FDA: no, EMA: no, PMDA: no
Description: Calcium supplementation (1000 mg/d)
Study: 7946871
Drug: Propofol (10
Approvals — FDA: no, EMA: no, PMDA: no
Description: Propofol (10 mg bolus followed by 30 mg/24 h infusion)
Study: 2519671
Drug: Permethrin-treated bednets
Normalized name: Permethrin
DrugBank: Permethrin (DB04930)
Approvals — FDA: yes, EMA: no, PMDA: no
Description: Permethrin-treated bednets (500 mg/m2)
Study: 31112621
Drug: I-neb (75
Approvals — FDA: no, EMA: no, PMDA: no
Description: I-neb (75 mg tobramycin inhalation solution)
Study: 31112621
Drug: PARI-LC Plus
Normalized name: formoterol
DrugBank: Formoterol (DB00983)
Approvals — FDA: yes, EMA: yes, PMDA: yes
Description: PARI-LC Plus (300 mg tobramycin inhalation solution)
Study: 16809994
Drug: Naloxone (0.8
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (0.8 mg intravenous bolus)
Study: 16809994
Drug: Naloxone (2-4
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2-4 mg given over 30 min)
Study: 16809994
Drug: Naloxone (2-3
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (2-3 mg bolus followed by continuous infusion of 4 mg/h)
Study: 16809994
Drug: Naloxone (5
Approvals — FDA: no, EMA: no, PMDA: no
Description: Naloxone (5 mg or greater)
Study: 10836723
Drug: Basal urinary
Approvals — FDA: no, EMA: no, PMDA: no
Description: Basal urinary excretion of cGMP in highly trained runners, sedentary subjects, and CAD patients
Study: 9180622
Drug: Placebo biofeedback
Approvals — FDA: no, EMA: no, PMDA: no
Description: Placebo biofeedback treatment
Study: 2579879
Drug: Oral propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Oral propafenone 300 mg t.i.d.
Study: 2579879
Drug: Intravenous propafenone
Approvals — FDA: no, EMA: no, PMDA: no
Description: Intravenous propafenone 1.5 mg/kg in three minutes.